In an adult patient with chronic hypertension, how does amlodipine compare to extended‑release nifedipine in terms of dosing, efficacy, side‑effect profile, and considerations for renal or hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Amlodipine vs Nifedipine in Chronic Hypertension

Amlodipine is the preferred choice over extended-release nifedipine for chronic hypertension due to superior once-daily dosing convenience, better patient compliance, fewer vasodilatory side effects, and comparable or superior blood pressure control.

Dosing Comparison

Amlodipine

  • Initial dose: 5 mg once daily 1
  • Maximum dose: 10 mg once daily 1
  • Dose adjustment: Wait 7-14 days between titration steps 1
  • Special populations: Start at 2.5 mg once daily in elderly, fragile, or hepatically impaired patients 1

Nifedipine Extended-Release

  • Typical dosing: 30-90 mg once daily 2
  • Important caveat: Three 30 mg tablets produce substantially higher peak concentrations than a single 90 mg tablet and should NOT be considered interchangeable 2
  • Food effect: High-fat meals increase peak concentration by 60% 2

Practical conversion: When switching from nifedipine ER to amlodipine, start with 5-10 mg once daily; approximately 60% of patients will require dose titration to achieve equivalent control 3

Efficacy

Both agents demonstrate equivalent blood pressure reduction in head-to-head trials 4. However, amlodipine achieves greater BP reduction per milligram of drug - showing 1.54 mmHg systolic and 0.57 mmHg diastolic reduction per mg, compared to nifedipine's lower potency requiring higher doses 5.

The 2024 ESC guidelines recommend dihydropyridine CCBs as first-line therapy for hypertension, without distinguishing between specific agents 6. Both drugs effectively reduce cardiovascular events when used appropriately.

Side Effect Profile

Amlodipine demonstrates a significantly superior tolerability profile:

  • 27% treatment-related side effects with amlodipine vs 41% with nifedipine retard (p<0.05) 7
  • Significantly fewer reports of headache and flushing with amlodipine 7
  • Fewer withdrawals due to adverse events with amlodipine 4, 7
  • Amlodipine's longer half-life (30-50 hours) produces more gradual vasodilation, reducing reflex tachycardia and vasodilatory symptoms 1

Common side effects for both include edema, palpitations, dizziness, and flushing, but these occur more frequently with nifedipine and at higher amlodipine doses (10 mg) 8.

Patient Compliance

Amlodipine's once-daily dosing produces markedly superior compliance compared to twice-daily nifedipine:

  • All four compliance assessment methods favored amlodipine in hypertensive patients 9
  • Amlodipine's 30-50 hour half-life maintains BP control even when a dose is missed, providing continuous protection during incidental non-compliance 8
  • Steady-state achieved after 7-8 days of consecutive dosing 1

Renal Impairment

Both agents are safe in renal impairment, with amlodipine having a slight practical advantage:

Amlodipine

  • Pharmacokinetics NOT significantly influenced by renal impairment 1
  • Patients with renal failure may receive the usual initial dose without adjustment 1
  • Low renal clearance (7 mL/min/mg) 8
  • Does not worsen kidney function in chronic kidney disease 8
  • Demonstrated renoprotective effects comparable to other antihypertensive classes 5

Nifedipine ER

  • No significant alterations in pharmacokinetics reported in hemodialysis or peritoneal dialysis patients 2
  • Caution advised as absorption may be modified by renal disease 2
  • In renal transplant recipients, both agents showed comparable effects on graft function 10

Hepatic Impairment

Both agents require dose reduction in hepatic impairment, but amlodipine has clearer dosing guidance:

Amlodipine

  • Start at 2.5 mg once daily in hepatic insufficiency 1
  • Clearance decreased with 40-60% increase in AUC 1
  • Specific FDA-approved dosing adjustment available

Nifedipine ER

  • Longer elimination half-life and higher bioavailability in liver cirrhosis 2
  • No specific dosing studied for nifedipine ER formulation in hepatic disease 2
  • Caution required but less clear guidance

Drug Interactions

Both are metabolized via CYP3A4. Key differences:

Amlodipine

  • 77% increase in simvastatin exposure - monitor closely 1
  • 40% average increase in cyclosporine levels in renal transplant patients 1
  • 2.5-4 fold increase in tacrolimus exposure in CYP3A5 expressers 1

Nifedipine

  • Up to 2-fold increase in AUC with grapefruit juice - avoid grapefruit completely 2
  • Similar CYP3A4 interactions expected

Special Populations

Elderly Patients

  • Both require lower starting doses 1, 2
  • Amlodipine: Start 2.5 mg daily 1
  • Elderly patients show 36% higher peak concentrations and 70% greater average plasma concentrations with amlodipine 1
  • Nifedipine elimination half-life nearly doubles in elderly (6.7h vs 3.8h) 2

Pregnancy

Neither agent is first-line for chronic hypertension in pregnancy (methyldopa, labetalol preferred).

Clinical Bottom Line

Choose amlodipine as first-line dihydropyridine CCB because:

  1. True once-daily dosing with forgiveness for missed doses
  2. 34% fewer side effects than nifedipine
  3. Superior patient compliance
  4. Clearer dosing guidance in hepatic impairment
  5. No food interaction concerns
  6. Higher potency per milligram
  7. Simpler titration schedule

Reserve nifedipine ER for:

  • Patients who have specifically failed or are intolerant to amlodipine
  • Cost considerations if generic nifedipine is substantially cheaper (though both are now generic)

The 2024 ESC guidelines support using dihydropyridine CCBs as first-line agents, preferably in combination therapy for most patients with confirmed hypertension (BP ≥140/90 mmHg) 6. When selecting between these two agents, amlodipine's practical advantages make it the superior choice for long-term chronic hypertension management.

References

Research

Amlodipine in the current management of hypertension.

Journal of clinical hypertension (Greenwich, Conn.), 2023

Research

Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.